PDCD1 and neoplasm: Cristescu’s study on pan-tumour genomic biomarkers for predicting clinical response to PD-1 checkpoint blockade indicated that TMB and T cell-inflamed gene expression profiles were independently predictive of response and showed weak correlation [61].